Analysts Issue Forecasts for Editas Medicine Q2 Earnings

Key Points

• Zacks Research raised its Q2 2026 EPS estimate for Editas Medicine to ($0.32) from ($0.34), while the broader outlook still points to continued losses for the biotech company.
• Analyst sentiment is mixed but generally constructive: the stock has a Moderate Buy consensus rating, with five Buy ratings, one Hold, and one Sell, and a consensus price target of $5.40.
• EDIT-401 appears to be a key catalyst, as Editas reported strong preclinical results and said it expects to submit a clinical trial notification by mid-2026, though a recent public offering adds dilution and financing pressure.

Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) - Research analysts at Zacks Research increased their Q2 2026 earnings per share estimates for shares of Editas Medicine in a research note issued on Tuesday, May 26th. Zacks Research analyst Team now expects that the company will post earnings per share of ($0.32) for the quarter, up from their prior estimate of ($0.34). The consensus estimate for Editas Medicine's current full-year earnings is ($1.08) per share. Zacks Research also issued estimates for Editas Medicine's Q3 2026 earnings at ($0.34) EPS, Q4 2026 earnings at ($0.33) EPS, FY2026 earnings at ($1.25) EPS, Q1 2027 earnings at ($0.34) EPS, FY2027 earnings at ($1.35) EPS, Q1 2028 earnings at ($0.36) EPS and FY2028 earnings at ($1.37) EPS.

A number of other brokerages also recently weighed in on EDIT. Wall Street Zen downgraded Editas Medicine from a "hold" rating to a "sell" rating in a research note on Sunday, May 10th. Weiss Ratings reissued a "sell (e+)" rating on shares of Editas Medicine in a research note on Monday, April 20th. Robert W. Baird set a $6.00 price objective on Editas Medicine in a research note on Monday, March 9th. JonesTrading raised Editas Medicine from a "hold" rating to a "buy" rating and set a $8.00 price objective on the stock in a research note on Tuesday, March 10th. Finally, Chardan Capital raised their price objective on Editas Medicine from $3.50 to $4.00 and gave the company a "buy" rating in a research note on Tuesday, May 5th. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $5.40.

Editas Medicine Stock Performance

Shares of EDIT stock opened at $3.57 on Thursday. The stock's 50 day simple moving average is $2.83 and its 200 day simple moving average is $2.43. Editas Medicine has a twelve month low of $1.60 and a twelve month high of $4.54. The company has a market capitalization of $349.54 million, a price-to-earnings ratio of -2.90 and a beta of 2.14.

Editas Medicine (NASDAQ:EDIT - Get Free Report) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.26) earnings per share for the quarter, beating analysts' consensus estimates of ($0.30) by $0.04. Editas Medicine had a negative return on equity of 677.39% and a negative net margin of 281.59%.The business had revenue of $2.83 million for the quarter, compared to the consensus estimate of $6.37 million.

Institutional Trading of Editas Medicine

A number of institutional investors and hedge funds have recently modified their holdings of the company. Renaissance Technologies LLC increased its position in shares of Editas Medicine by 30.7% during the first quarter. Renaissance Technologies LLC now owns 3,972,160 shares of the company's stock valued at $9,811,000 after purchasing an additional 932,382 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Editas Medicine by 122.2% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,600,000 shares of the company's stock valued at $3,016,000 after purchasing an additional 1,430,000 shares during the period. Geode Capital Management LLC increased its position in shares of Editas Medicine by 12.0% during the fourth quarter. Geode Capital Management LLC now owns 2,284,740 shares of the company's stock valued at $4,685,000 after purchasing an additional 244,574 shares during the period. State Street Corp increased its position in shares of Editas Medicine by 2.6% during the fourth quarter. State Street Corp now owns 1,974,931 shares of the company's stock valued at $4,049,000 after purchasing an additional 49,887 shares during the period. Finally, Two Sigma Investments LP boosted its stake in Editas Medicine by 63.3% in the 3rd quarter. Two Sigma Investments LP now owns 1,584,155 shares of the company's stock valued at $5,497,000 after buying an additional 614,229 shares in the last quarter. 71.90% of the stock is currently owned by institutional investors.

Editas Medicine News Summary

Here are the key news stories impacting Editas Medicine this week:

• Positive Sentiment: Investors showed strong speculative interest, with unusually heavy call buying suggesting some traders are positioning for further upside in Editas Medicine (EDIT).
• Positive Sentiment: HC Wainwright reiterated a bearish earnings outlook but the note did not materially worsen the company’s already negative profit profile, while keeping attention on future pipeline execution rather than near-term earnings.
• Positive Sentiment: Editas reported promising preclinical data for EDIT-401, showing ~90% or greater reductions in LDL-C, Lp(a), and ApoB in non-human primates, which supports the drug’s potential in hyperlipidemia and cardiovascular risk reduction. Article Title
• Positive Sentiment: The company also said it is on track to submit a clinical trial notification by mid-2026 and expects early human proof-of-concept data by year-end, which may reinforce optimism around its lead program. Article Title
• Negative Sentiment: Editas priced an underwritten public offering of more than 55.5 million shares plus warrants, which is pressuring the stock because it increases dilution risk for existing shareholders. Article Title
• Negative Sentiment: The company also suspended and terminated a prior at-the-market offering program, underscoring its ongoing need to raise capital and highlighting financing overhangs. Article Title

Editas Medicine Company Profile

Editas Medicine is a clinical-stage biotechnology company focused on translating the power of gene editing into a new class of transformative genomic medicines. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company leverages proprietary CRISPR/Cas9 and CRISPR/Cas12a (Cpf1) platforms to develop therapies aimed at correcting disease-causing genetic mutations. Editas Medicine's research and development efforts span multiple therapeutic areas, including inherited retinal diseases, hemoglobinopathies, and oncology.

The company's pipeline includes EDIT-101, a lead candidate designed to treat Leber congenital amaurosis type 10 (LCA10), which has entered early-stage clinical trials, and EDIT-301, targeting sickle cell disease and β-thalassemia using an ex vivo editing approach.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.